# Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass

> **NCT02239146** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 43 (actual)

## Conditions studied

- Acquired Bleeding Disorder
- Cardiac Surgery Requiring Cardiopulmonary Bypass

## Interventions

- **DRUG:** catridecacog
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02239146
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02239146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02239146, "Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02239146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*